FDA Compliance for Peptide Therapy and BPC 157 Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling